Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD.
Under the agreement, Milan, Italy-based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.